China's biotech overseas technology transfer agreements reached $137.7 billion in 2025, nearly ten times the 2021 figure, as global drugmakers rush to acquire Chinese candidates. BeiGene's Brukinsa surpassed $4 billion in global sales, while Pfizer agreed to a deal with Innovent Biologics worth up to $10.5 billion. U.S. lawmakers are raising security concerns about growing dependence on Chinese biotech.
Onco-Innovations has begun scaling production of A83B4C63, the API in its lead cancer drug ONC010, to kilogram quantities at Dalton Pharma Services' Toronto facility to support IND-enabling studies. The company's subsidiary Inka Health signed AI research agreements with AstraZeneca and GlaxoSmithKline, and plans a first-in-human study in 2026 pending a pre-IND meeting with the FDA.
A Washington federal judge declined to block a state law expanding 340B drug pricing discounts, rejecting Novartis and AbbVie's arguments that it illegally adds to their obligations under the federal program aimed at protecting low-income patients.
Twenty years after HPV vaccine approval, head and neck cancers have become the most common HPV-related cancer with 16,000 cases annually. The incidence tripled from 2000 to 2017, primarily affecting men in their 40s to 60s. Vaccination rates among teens reached approximately 77-79% for at least one dose in 2024.
Rare diseases affect an estimated 25-30 million Americans, yet 95% lack FDA-approved treatments. Families affected by conditions like SLC6A1-related disorders and Anti-IgLON5 Autoimmune Encephalitis voice concerns about drug pricing policies that could slow medical innovation. Advocates urge lawmakers to protect research investment while sharing stories of diagnostic challenges and treatment breakthroughs.
FDA announced a pilot program in April 2026 to enable real-time data review during clinical trials, aiming to significantly reduce drug approval timelines. Industry experts emphasized the benefits of direct data capture and AI-driven site selection while cautioning about potential accuracy concerns with early signal detection.
NASA announced the four-member Artemis III crew, who will test lunar lander rendezvous and docking operations ahead of the 2028 moon landing attempt. The mission faces uncertainty as Blue Origin recovers from a launch pad explosion and SpaceX continues developing its lander system. Space medicine experts note that deeper missions will require astronauts to manage medical care independently without Earth support.
The Australian government announced an additional $387.4 million for CSIRO over four years and $12.7 million for eight quantum technology projects under the Critical Technologies Challenge Program, part of its broader National Quantum Strategy commitment.
Biotech stocks Ocugen, Kodiak Sciences, and CytoDyn are experiencing market movements driven by clinical data and regulatory milestones, particularly Biologics License Application (BLA) filings. Ocugen saw a surge in short interest, Kodiak reached a 52-week high on positive trial results, and CytoDyn's stock remains volatile as it advances its monoclonal antibody pipeline.
Maryland biotech leaders outlined a strategy to scale the state's life sciences ecosystem, focusing on community building, investor attraction, and federal alignment. Meanwhile, 18 states face limited access to HIV treatment assistance programs due to stagnant federal funding amid rising costs.
AI-driven feasibility tools are cutting clinical trial site selection timelines from months to weeks by analysing historical data, enrolment benchmarks, and geographic trends. Clinical trial pharmacy software platforms are integrating with management systems and incorporating AI, machine learning, and blockchain to improve medication tracking, regulatory compliance, and data security across global trials.
Updated data from the phase I CaMMouflage trial showed CB-011, the first allogeneic anti-BCMA CAR-T therapy with immune cloaking, achieved an approximately 92% overall response rate in relapsed/refractory multiple myeloma. The 2026 Tandem Meetings also highlighted advances in EB-103, KITE-753, and LV20.19 CAR-T constructs across lymphoma and CLL. Separately, NXC-201 reported a 95% complete response rate in AL amyloidosis.
MoonLake Immunotherapeutics plans to submit an FDA Biologics License Application for Sonelokimab in hidradenitis suppurativa by the end of September following a positive pre-BLA meeting. The submission is supported by clinical trial data showing 43% of patients achieved high-level improvement by Week 12 in the Mira trial. The company is also expecting multiple Phase 3 data readouts throughout the year.
Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.
BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven analytics into an ADC development program. The company also revealed six abstracts will be presented at the EHA 2026 Congress in Stockholm. The research showcases integrated multiomics and predictive modeling for blood cancer treatment optimization.
Global drugmakers are expanding rare disease research investment in Brazil, attracted by new regulations, genetic diversity, and the public healthcare system's data capabilities. Major companies including AstraZeneca, Biogen, and Roche have committed significant clinical research budgets to the country. Despite this progress, advocates warn that a significant global funding gap persists, with 95% of rare diseases still lacking an FDA-approved treatment.
The FDA is receiving extensive industry feedback on three regulatory initiatives: draft guidance for using new approach methodologies to reduce animal testing, the Commissioner's National Priority Voucher pilot program, and a proposed rule to update the National Drug Code format. Stakeholders are urging revisions to the NAMs guidance, improvements to the CNPV program, and timely finalization of the NDC rule to avoid disruptions.
The U.S. Congress is advancing three legislative and regulatory measures to scrutinize and potentially restrict partnerships between American biopharma companies and Chinese biotech firms, citing national security concerns. These actions target the flow of U.S. capital and technology to China amid a surge in deals, with innovative drug out-licensing transactions exceeding $60 billion in the first quarter of 2026 alone.
A new "expand and pull" treatment strategy combines long-acting interleukin-7 and oncolytic virus therapy to boost T cell response in glioblastoma. In mouse models, the combination improved cytotoxic T cell function and led to long-term tumor-free survival.
Sangamo Therapeutics has retained Raymond James to evaluate strategic alternatives to advance its pipeline and maximize stakeholder value. Key assets include the BLA-ready Fabry disease gene therapy ST-920, the STAC-BBB capsid platform generating $88M in fees to date, and multiple neurology programs. No transaction has been agreed and no timetable has been set.
